Introduction
============

Brain metastases (BMs), the most common neurological complication, develop in 20--40% of patients with cancer ([@b1-mco-0-0-1152]). In 40--50% of these patients, the dominant primary tumor was lung cancer (LC) ([@b2-mco-0-0-1152]). Patients with LC who presented BMs at their initial primary tumor diagnosis had a poor prognosis in untreated patients ([@b3-mco-0-0-1152],[@b4-mco-0-0-1152]). Surgery, whole brain radiation therapy (WBRT) and stereotactic radiosurgery (SRS) were frequently applied to the treatment of BMs. A limited number (predominantly 1--3 and in certain cases \>3) of BMs can be effectively intervened by surgical resection or SRS ([@b5-mco-0-0-1152],[@b6-mco-0-0-1152]). However, a considerable proportion of patients, being unsuitable for surgery or SRS, were controlled using a palliative approach, including WBRT, to improve neurological symptoms and local lesions. Unfortunately, radiotherapy can only prolong the median survival time to 6 months for LC patients with BMs ([@b7-mco-0-0-1152]). Therefore, establishing a multimodality therapy, including targeted agents or chemotherapy plus radiotherapy, is urgently required to maximize the therapeutic effect. Accordingly, certain relevant trials ([@b8-mco-0-0-1152],[@b9-mco-0-0-1152]) combining antitumor agents with radiotherapy have been performed in recent decades. Some of these treatments demonstrated favorable efficacy and safety of antitumor agents plus radiotherapy in dealing with BMs ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152]--[@b17-mco-0-0-1152]), while other trials failed to confirm this ([@b18-mco-0-0-1152]--[@b21-mco-0-0-1152]). The role of antitumor agents plus radiotherapy for managing BMs remains controversial. Therefore, the present study performed a meta-analysis to investigate the efficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for BMs from lung cancer, to optimize the therapeutic strategy.

Materials and methods
=====================

### Data sources and search

A thorough search in PubMed was performed without language restriction from inception until October 2015 using the following keywords and Mesh terms: \['anti-tumor agents' (all fields) OR 'anti-cancer drugs' (all fields)\] AND \['EGFR tyrosine kinase inhibitors' (all fields) OR 'epidermal growth factor receptor' (all fields) OR 'targeted agents' (all fields)\] AND \['chemotherapy' (all fields) AND 'irradiation' (all fields) OR 'radiation therapy' (all fields) OR 'radiotherapy' (all fields) OR 'radiotherapeutics' (all fields)\] AND \['lung cancer' (Mesh) OR 'lung neoplasms' (Mesh) OR 'lung carcinoma' (Mesh)\] AND \['brain metastases' (Mesh) OR 'intracranial metastases' (Mesh) OR 'intracranial metastatic tumor' (Mesh) OR 'brain neoplasms' (Mesh)'\]. All reviews, and preclinical and animal trials were excluded.

### Study selection

Eligible trials were those that met the following criteria: i) Randomized controlled trials (RCTs) or clinical controlled trails with voluntarily enrolled patients; ii) Patients suffered from histologically or cytologically confirmed lung cancer and had been diagnosed with brain metastases using computed tomography (CT) or magnetic resonance imaging (MRI); iii) The trials were anti-tumor agents plus radiotherapy (WBRT/SRS or in combination) which were considered as combination group vs. radiotherapy alone group; iv) Trials excluded patients with double or multiple primary cancer or presence of unstable systemic disease; v) The analyses included objective response rate (ORR), overall survival (OS), progression-free survival (PFS), time to central nervous system/neurological progression (CNS-TTP)/neurological PFS/progression-free survival of intracranial disease/local progression-free survival/interval to neurologic progression (all were assigned to CNS-TTP in the present study), severe adverse events (AEs; Grade ≥3); vi) Response rate was determined using the Response Evaluation Criteria in Solid Tumors (RECIST 1.0 or 1.1 standards) or World Health Organization (WHO) criteria ([@b11-mco-0-0-1152]--[@b13-mco-0-0-1152],[@b15-mco-0-0-1152],[@b17-mco-0-0-1152],[@b18-mco-0-0-1152],[@b21-mco-0-0-1152]); vii) Adverse events were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE 2.0 or 3.0) or Radiation Therapy Oncology Group (RTOG) adverse events grading criteria ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152]--[@b12-mco-0-0-1152],[@b14-mco-0-0-1152],[@b15-mco-0-0-1152],[@b17-mco-0-0-1152]--[@b21-mco-0-0-1152]).

### Data extraction and quality assessment

For each selected publication, the following information was extracted: First author, year of publication, country of original trial, type of trial, trial phase, number of patients, median ages, interventions and outcomes. To assess the quality and applicability of each previous study, checklists from The Cochrane Handbook for Systematic Reviews of intervention (version 5.1.0) were used, based on the following criteria: i) Random sequence generation; ii) Allocation concealment; iii) Blinding of participants and personnel; iv) Blinding of outcome assessment; v) Incomplete outcome data; vi) Selective reporting; vii) Other bias. Each trial for bias based on the criteria listed above was marked as low, high or unclear risk. The quality of the trails were defined as following: A rating, meeting all criteria of low risk; B rating, meeting one or more criteria of unclear risk without high risk; C rating, meeting one or more criteria of high risk.

### Statistical analysis

Statistical analysis was performed using RevMan 5.3 software (Cochrane Collaboration\'s, which is a non-profit and non-governmental organization, Information Management System). Analysis of the data comprised of the pooled risk ratio (RR) for dichotomous endpoints (e.g., ORR, severe AEs), using the Mantel-Haenszel method ([@b22-mco-0-0-1152]). The events and total number of patients from the combination group and radiotherapy alone group in the trials for ORR and severe AEs were extracted from the trials ([@b10-mco-0-0-1152]--[@b15-mco-0-0-1152], [@b17-mco-0-0-1152]--[@b21-mco-0-0-1152]). OS, PFS and CNS-TTP were calculated using effect variables and expressed as the hazard ratio (HR). HRs with 95% confidence intervals (CIs) were extracted from trials or from the survival curves using the methods described by Tierney *et al* ([@b23-mco-0-0-1152]) for OS, PFS and CNS-TTP when HRs were unavailable. The 95% CIs were calculated and presented in forest plots. Statistical heterogeneity of different trials was evaluated using the χ^2^ and I^2^ tests ([@b24-mco-0-0-1152]); no heterogeneity existed when P\>0.1 and I^2^\<50% and a fixed-effect model was applied to pool the study results. Significant heterogeneity was found if P\<0.1 or I^2^\>50%, and a random-effects statistical model was used ([@b25-mco-0-0-1152]). The risk of publication bias was evaluated via visual appraisal of funnel plots.

Results
=======

### Study characteristics

A total of 1,412 previous studies met the selection criteria after searching the relevant databases. By verifying related terms in the titles and abstracts, 1,302 irrelevant articles and another 97 articles with an unfit design were excluded after the full text was analyzed. Finally, 13 clinical controlled trials ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152]--[@b21-mco-0-0-1152]) were included in the present meta-analysis. A flowchart depicting inclusion is shown in [Fig. 1](#f1-mco-0-0-1152){ref-type="fig"}.

In these 13 controlled trials, 1,783 patients with BMs were observed, including 853 patients with antitumor agents plus radiotherapy and 930 patients with radiotherapy alone. These results are summarized in [Table I](#tI-mco-0-0-1152){ref-type="table"}. Among these 13 trials, 5 were phase III clinical trials ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152],[@b11-mco-0-0-1152],[@b20-mco-0-0-1152],[@b21-mco-0-0-1152]), 6 phase II trials ([@b12-mco-0-0-1152],[@b14-mco-0-0-1152],[@b15-mco-0-0-1152],[@b17-mco-0-0-1152]--[@b19-mco-0-0-1152]) and 2 studies failed to mention a trial phase ([@b13-mco-0-0-1152],[@b16-mco-0-0-1152]). Of these trails, 11 involved an antitumor agents plus WBRT, compared with WBRT alone ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152]--[@b15-mco-0-0-1152],[@b17-mco-0-0-1152]--[@b19-mco-0-0-1152],[@b21-mco-0-0-1152]), and the others included antitumor agents combined with WBRT plus SRS, compared with WBRT plus SRS ([@b16-mco-0-0-1152],[@b20-mco-0-0-1152]). Outcomes included ORR, OS, PFS, CNS-TTP and severe AEs.

Data for all characteristics are summarized in [Table II](#tII-mco-0-0-1152){ref-type="table"}. Gender, Karnofsky performance score, number of BMs, extracranial metastases, histology, epidermal growth factor receptor mutation status and recursive partitioning analysis were available for 11, 4, 3, 8,7, 2 and 5 of the 13 trials, respectively.

### Methodological quality

In accordance with the recommendations of the Cochrane Handbook for Systematic Reviews, the present study assessed the eligible trials using the seven aspects mentioned above. Among these 13 recruited trials, ten ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152]--[@b11-mco-0-0-1152],[@b13-mco-0-0-1152]--[@b15-mco-0-0-1152],[@b18-mco-0-0-1152]--[@b21-mco-0-0-1152]) referred to the use of random allocation, three discussed the methods ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152],[@b13-mco-0-0-1152]), two ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152]) performed or reported their blinding methods and two ([@b18-mco-0-0-1152],[@b19-mco-0-0-1152]) reported their allocation concealment. All trials applied the intent-to-treat analysis and underwent quality assessment. Eventually, three ([@b10-mco-0-0-1152],[@b13-mco-0-0-1152],[@b14-mco-0-0-1152]) received B quality scores and 10 ([@b3-mco-0-0-1152],[@b11-mco-0-0-1152],[@b12-mco-0-0-1152],[@b15-mco-0-0-1152]--[@b21-mco-0-0-1152]) received C quality scores, as shown in [Fig. 2](#f2-mco-0-0-1152){ref-type="fig"}.

### Local response rate

A total of seven trials ([@b11-mco-0-0-1152]--[@b13-mco-0-0-1152],[@b15-mco-0-0-1152],[@b17-mco-0-0-1152],[@b18-mco-0-0-1152],[@b21-mco-0-0-1152]) testing response rate of treatment using antitumor agents plus radiotherapy compared with radiotherapy alone were identified. A fixed-effect model was utilized for the meta-analysis since heterogeneity did not exist (P=0.21; I^2^=28%). Notably, pooled data from the study results revealed a significant difference in terms of ORR between the groups of patients who were treated with antitumor agents plus radiotherapy and those who had received radiotherapy alone (RR, 1.38; 95% CI, 1.19--1.60; P\<0.0001) ([Fig. 3](#f3-mco-0-0-1152){ref-type="fig"}). Subgroup analysis of radiochemotherapy vs. radiotherapy alone demonstrated a significant ORR benefit for the radiochemotherapy arm (RR, 1.38; 95% CI, 1.09--1.75; P=0.007) ([Fig. 3](#f3-mco-0-0-1152){ref-type="fig"}). By contrast, a higher ORR (P=0.07) trend favoring targeted drugs plus radiotherapy group was observed ([@b15-mco-0-0-1152],[@b17-mco-0-0-1152]) despite the existence of heterogeneity (P=0.06; I^2^=73%) ([Fig. 4](#f4-mco-0-0-1152){ref-type="fig"}).

### Time to central nervous system progression

A total of seven trials ([@b3-mco-0-0-1152],[@b10-mco-0-0-1152],[@b12-mco-0-0-1152],[@b14-mco-0-0-1152],[@b16-mco-0-0-1152],[@b17-mco-0-0-1152],[@b19-mco-0-0-1152]) reported time to central nervous system progression (CNS-TTP) in both groups. A random-effects model was applied based on the heterogeneity values (P=0.04, I^2^=54%). The outcome suggested that compared with radiotherapy alone, antitumor agents plus radiotherapy possessed a superior CNS-TTP for patients (HR, 0.71; 95% CI, 0.57--0.90; P=0.004) ([Fig. 5](#f5-mco-0-0-1152){ref-type="fig"}). The subgroup analysis obtained a similar superior CNS-TTP in the tyrosine kinase inhibitor (TKI) plus radiotherapy group, compared with the radiotherapy alone group (HR, 0.58; 95% CI, 0.35--0.97; P=0.04), although heterogeneity existed among them (P=0.03, I^2^=71%) ([Fig. 5](#f5-mco-0-0-1152){ref-type="fig"}). Additionally, the prolonged CNS-TTP also appeared in the chemotherapy plus radiotherapy group (HR, 0.80; 95% CI, 0.67--0.96; P=0.02) without heterogeneity (P=0.76, I^2^=0%). Details of this pooled analysis are shown in [Fig. 6](#f6-mco-0-0-1152){ref-type="fig"}.

### Survival

A total of 11 trials ([@b11-mco-0-0-1152]--[@b21-mco-0-0-1152]) reported OS in both groups. Owing to the heterogeneity values (P=0.0002, I^2^=70%), a random-effects model was employed to analyze OS and no significantly longer OS was observed in the antitumor agents plus radiotherapy group compared with that in radiotherapy alone group (HR, 0.80; 95% CI, 0.61--1.05; P=0.11) ([Fig. 7](#f7-mco-0-0-1152){ref-type="fig"}). The funnel plot indicated no significant publication bias for OS ([Fig. 8](#f8-mco-0-0-1152){ref-type="fig"}). Additionally, no prolonged OS was observed in the chemotherapy plus radiotherapy group compared with the radiotherapy alone group (HR, 0.96; 95% CI, 0.79--1.17; P=0.68) ([Fig. 9](#f9-mco-0-0-1152){ref-type="fig"}). Notably, the OS of the targeted agents plus radiotherapy was significantly superior to radiotherapy alone (HR, 0.58; 95% CI, 0.37--0.90; P=0.01) with an important heterogeneity (P=0.02, I^2^=69%) ([Fig. 7](#f7-mco-0-0-1152){ref-type="fig"}). A total of four trials ([@b11-mco-0-0-1152],[@b12-mco-0-0-1152],[@b17-mco-0-0-1152],[@b18-mco-0-0-1152]) reporting PFS were analyzed applying a fixed-effect model based on the heterogeneity values (P=0.52, I^2^=0%) and revealed that, compared with radiotherapy alone, antitumor agents plus radiotherapy significantly prolonged PFS (HR, 0.60; 95% CI, 0.44--0.83; P=0.002) ([Fig. 10](#f10-mco-0-0-1152){ref-type="fig"}).

### Adverse events

Of the included trials, eight ([@b10-mco-0-0-1152]--[@b12-mco-0-0-1152],[@b14-mco-0-0-1152],[@b17-mco-0-0-1152]--[@b20-mco-0-0-1152]) with sufficient data of treatment-related toxicity and severe AEs grading were applied to analyze AEs. A random-effects model was used to analyze overall severe AEs based on the heterogeneity values (P\<0.0001, I^2^=81%). The results indicated that antitumor agents plus radiotherapy elevated the incidence of overall severe AEs (RR, 2.57; 95% CI, 1.24--5.35; P=0.01) ([Fig. 11](#f11-mco-0-0-1152){ref-type="fig"}). Consequently, the present study performed a subgroup analysis for the severe AEs ([Figs. 12](#f12-mco-0-0-1152){ref-type="fig"} and [13](#f13-mco-0-0-1152){ref-type="fig"}). Hematotoxicity was the most common AE in the antitumor agents plus radiotherapy group. A notably higher incidence of grade III--IV leukopenia (RR, 7.01; 95% CI, 1.37--35.75; P=0.02) and thrombocytopenia (RR, 9.86; 95% CI, 1.97--49.37; P=0.005) was observed in the antitumor agents plus radiotherapy group. However, the most common non-hematological AEs, which were largely mild and tolerable without significant difference between antitumor agents plus radiotherapy and radiotherapy alone, including fatigue/asthenia (RR, 0.82; 95% CI, 0.33--2.06; P=0.67), dyspnea (RR, 1.65; 95% CI, 0.32--8.63; P=0.55), pain (RR, 1.28; 95% CI, 0.27--6.14; P=0.76), myopathy (RR, 0.72; 95% CI, 0.14--3.67; P=0.70), nausea/vomiting (RR, 1.61; 95% CI, 0.73--3.54; P=0.23) and infection (RR, 2.19; 95% CI, 1.00--4.78; P=0.05) ([Fig. 13](#f13-mco-0-0-1152){ref-type="fig"}). Additionally, no severe hematotoxicity was observed in both the targeted agents plus radiotherapy group and the radiotherapy alone group.

Discussion
==========

Since radiation therapy only acquires limited local control of BMs, it is reasonable to make an attempt to combine antitumor agents with radiotherapy to maximize efficacy. Theoretically, due to the effect of the blood-brain barrier (BBB), the majority of chemotherapeutic agents were unable to reach sufficient concentration in BMs lesions ([@b26-mco-0-0-1152]), and LC patients with BMs may not gain benefit from these agents. However, previous clinical studies demonstrated that temozolomide, tegafur, chloroethyl nitrosoureas (methyl-CCNU or ACNU) and topotecan were effective in dealing with BMs, which partly derived from the distinctive property of the drugs, including their high capacity of penetrating the BBB and unique antitumor mechanisms ([@b27-mco-0-0-1152]--[@b33-mco-0-0-1152]). These interesting findings have inspired oncologists to design modality of combining antitumor agents with radiotherapy.

The present study demonstrated that antitumor agents plus radiotherapy possessed a significant benefit in terms of ORR, CNS-TTP and PFS, which may have a potential application value for LC patients with BMs. In addition, subgroup analysis also revealed superior ORR and CNS-TTP in the chemoradiotherapy group to radiotherapy alone group. The clinical outcomes may be elaborated by the following mechanisms: i) Radiotherapy, immature tumor angiogenesis and edema may amplify the destruction of the BBB and result in increasing permeability of the BBB ([@b34-mco-0-0-1152]--[@b36-mco-0-0-1152]); ii) certain antitumor agents own radiosensitizing effects ([@b37-mco-0-0-1152],[@b38-mco-0-0-1152]); iii) the tumor growth may disrupt the BBB ([@b39-mco-0-0-1152]).

Furthermore, the present study demonstrated that targeted agents plus radiotherapy prolonged the OS without severe hematotoxicity. The mechanisms may be as follows: i) Smaller molecular targeted agents possess a high capacity of penetrating the BBB ([@b40-mco-0-0-1152],[@b41-mco-0-0-1152]); ii) targeted agents have synergistic effect with radiotherapy in managing BMs ([@b42-mco-0-0-1152]); iii) unlike chemotherapy agents, targeted agents own a high selectivity against cancer cells, which partly accounts for the mild and low toxicity of this regimen ([@b43-mco-0-0-1152]).

Undoubtedly, cytotoxic agents inhibited bone marrow cells, which accounted for the hematotoxicity observed in patients treated with chemotherapy, while EGFR-TKI therapy frequently resulted in mild and reversible acne rash and diarrhea ([@b44-mco-0-0-1152]). Compared with standard chemotherapy, the milder the toxicity profile was produced by EGFR-TKI, the less quality of life was intervened ([@b45-mco-0-0-1152]). Additionally, the higher risk of treatment interruption due to severe AEs in radiochemotherapy may partly explain its unfavorable OS.

In conclusion, the present study demonstrated that targeted agents plus radiotherapy yielded desirable effects with mild AEs. Therefore, it is advisable to combine targeted agents with radiotherapy to deal with inoperable BMs from LC. Secondary to best, chemoradiotherapy is an alternative option for patients without suitable molecular targets.
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###### 

Characteristics of the trials included in the metaanalysis.

                                                                    Interventions           Outcomes                             
  ------------------------- ----------- ----- --------- ----------- ----------------------- ---------------- --- --- --- --- --- -----------------------
  Mehta *et al*, 2003       America     III   123/128   N           MGd + WBRT              WBRT             N   N   Y   N   Y   ([@b3-mco-0-0-1152])
  Mehta *et al*, 2009       America     III   279/275   59/59       MGd + WBRT              WBRT             N   N   Y   N   Y   ([@b10-mco-0-0-1152])
  Neuhaus *et al*, 2009     Germany     III   47/49     58/59       Topotecan + WBRT        WBRT             Y   Y   N   Y   Y   ([@b11-mco-0-0-1152])
  Ge *et al*, 2013          China       II    38/38     59/60.5     Topotecan + WBRT        WBRT             Y   Y   Y   Y   Y   ([@b12-mco-0-0-1152])
  Ushio *et al*, 1991       Japan       N     29/25     58/63       CENU + tegafur + WBRT   WBRT             Y   Y   N   N   N   ([@b13-mco-0-0-1152])
  Lee *et al*, 2014         UK          II    40/40     61.3/62.2   Erlotinib + WBRT        Placebo + WBRT   N   Y   Y   N   Y   ([@b14-mco-0-0-1152])
  Jiang *et al*, 2014       China       II    40/40     67/64       Endostatin + WBRT       WBRT             Y   Y   N   N   Y   ([@b15-mco-0-0-1152])
  Cai *et al*, 2014         China       N     104/178   65/65       TKI+ WBRT/SRS/S         WBRT/SRS/S       N   Y   Y   N   N   ([@b16-mco-0-0-1152])
  Zhuang *et al*, 2013      China       II    23/31     60/63       Erlotinib + WBRT        WBRT             Y   Y   Y   Y   Y   ([@b17-mco-0-0-1152])
  Hassler *et al*, 2013     Austria     II    22/13     69/64       TMZ + WBRT              WBRT             Y   Y   N   Y   Y   ([@b18-mco-0-0-1152])
  Chua *et al*, 2010        China       II    47/48     59/62       TMZ + WBRT              WBRT             N   Y   Y   N   Y   ([@b19-mco-0-0-1152])
  Sperduto *et al*, 2013    America     III   40/44     63/64       TMZ + WBRT + SRS        WBRT+ SRS        N   Y   N   N   Y   ([@b20-mco-0-0-1152])
  Guerrieri *et al*, 2004   Australia   III   21/21     60/63       Carboplatin + WBRT      WBRT             Y   Y   N   N   Y   ([@b21-mco-0-0-1152])

C/R, combination group/radiotherapy alone group; TKI, tyrosine kinase inhibitors; TMZ, temozolomide; MGd, motexafin gadolinium; CENU, chloroethyl nitrosoureas; WBRT, whole brain radiation therapy; SRS, stereotactic radiosurgery; S, surgery; ORR, objective response rate; OS, overall survival; CNS-TTP, time to central nervous system progression; PFS, progressionfree survival; AEs, adverse events; N, no mention in the paper; Y, mentioned in the paper.

###### 

Patient characteristics.

  Characteristics           Cgroup (%) n=853   Rgroup (%) n=930
  ------------------------- ------------------ ------------------
  Gender                                       
    Male                    414 (49)           454 (49)
    Female                  276 (32)           304 (33)
    Unknown                 163 (19)           172 (18)
  KPS                                          
    ≥70                     389 (46)           394 (42)
    \<70                    0 (0)              0 (0)
    Unknown                 464 (54)           536 (58)
  No. of BMs                                   
    ≤3                      82 (10)            87 (9)
    \>3                     36 (4)             35 (4)
    Unknown                 735 (86)           808 (87)
  Extracranial metastases                      
    Yes                     331 (39)           393 (42)
    No                      287 (34)           310 (33)
    Unknown                 235 (27)           227 (25)
  Histology                                    
    Adenocarcinoma          348 (41)           403 (43)
    Squamous                64 (7)             72 (8)
    Other                   92 (11)            88 (9)
    Unknown                 349 (41)           367 (40)
  EGFR mutation                                
    Positive                40 (5)             26 (3)
    Negative                33 (4)             33 (3)
    Unknown                 780 (91)           871 (94)
  RPA                                          
    I                       57 (7)             55 (6)
    II                      347 (41)           348 (37)
    Unknown                 449 (52)           527 (57)

KPS, Karnofsky performance score; BM, brain metastases; EGFR, epidermal growth factor receptor; RPA, recursive partitioning analysis; Cgroup, combination group; Rgroup, radiotherapy alone group.
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